Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist?
Authors:
- Caterina VivaldiCVCaterina Vivaldi
- Silvia CataneseSCSilvia Catanese
- Valentina MassaVMValentina Massa
- Irene PecoraIPIrene Pecora
- Francesca SalaniFSFrancesca Salani
- Stefano SantiSSStefano Santi
- Monica LencioniMLMonica Lencioni
- Enrico VasileEVEnrico Vasile
- Alfredo FalconeAFAlfredo Falcone
- Lorenzo FornaroLFLorenzo Fornaro
Open Access
- 28 February 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (5) , 1658
Abstract
Esophageal cancer remains a challenging disease due to limited treatment options and poor prognosis. In recent years, immune checkpoint inhibitors (ICI) have been proven to be safe and effective in the treatment of highly lethal malignancies, such as non-small cell lung cancer and melanoma. Recent clinical trials also showed promising activity in immune checkpoint inhibitors in pretreated advanced esophageal carcinoma and a potentially significant impact on the outcome of selected patients, independently of histology. Combination studies evaluating immunotherapy and chemotherapy and, in localized disease, radiotherapy are in progress and will hopefully confirm their promises in the near future. However, reliable predictive biomarkers are still lacking. Indeed, at present, the role of programmed cell death ligand 1 expression and other factors (such as microsatellite instability and tumor mutational burden) as predictive biomarkers of benefit to immune checkpoint inhibitors is still controversial. Our aim was to explore the rationale of ICIs in esophageal cancer, review the results already available in multiple settings, and investigate future perspectives with single-agent and combination strategies.Keywords
This publication has 69 references indexed in Scilit:
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- Preoperative Chemoradiotherapy for Esophageal or Junctional CancerNew England Journal of Medicine, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Esophageal Cancer: A Critical Evaluation of Systemic Second-Line TherapyJournal of Clinical Oncology, 2011
- The clinical importance of emerging Campylobacter speciesNature Reviews Gastroenterology & Hepatology, 2011
- A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapyCancer Chemotherapy and Pharmacology, 2010
- Influence of neoadjuvant radio-chemotherapy on tumor-infiltrating lymphocytes in squamous esophageal cancerEuropean Journal of Surgical Oncology, 2009
- Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivoNature Biotechnology, 2009
- Immune surveillance of tumorsJournal of Clinical Investigation, 2007
- A phase II study of single-agent docetaxel in patients with metastatic esophageal cancerAnnals of Oncology, 2004